Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Urodynamix Technologies announces fiscal 2009 second-quarter financials

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today reported its financial results for its fiscal second quarter ended June 30, 2009. The Company reported revenues of $21,871, a 70% decrease over the same quarter of the prior year. The Company's order backlog at June 30, 2009 was $92,576 compared to nil at the end of the comparative quarter June 30, 2008.

28 Aug 2009

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

TomoTherapy Incorporated announced today that there will be more than 40 presentations at the 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy that explore use of the TomoTherapy treatment system. The TomoTherapy system -- a versatile, CT scanner-based device that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting -- is helping cancer centers advance patient care around the world.

28 Aug 2009

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Fatostatin lowers the activity of genes associated with cholesterol synthesis

A small molecule earlier found to have both anti-fat and anti-cancer abilities works as a literal turnoff for fat-making genes, according to a new report in the August 28th issue of the journal Chemistry and Biology, a Cell Press journal.

27 Aug 2009

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Resonant Medical, an innovator in soft tissue planning, image-guidance and adaptive radiotherapy products, today announced that the Company will be exhibiting the next generation of its multi-anatomy Clarity System at the 10th Biennial Meeting of The European Society of Therapeutic Radiology and Oncologists (ESTRO), being held in Maastricht, Netherlands.

27 Aug 2009

oBand uses the da Vinci Surgical System to perform the world's first robotic surgery in an outpatient surgical center

oBand Surgery Centers, the nation's leading bariatric network of outpatient surgical facilities owned and operated by nationally recognized Lap Band surgeons, has set a new 'first' in the use of robotics for outpatient surgery. oBand Director of Robotic Surgery S. Adam Ramin, M.D., an assistant professor at City of Hope National Medical Center, today announced they have performed the world's first, outpatient robotic surgery using the famed da Vinci® Surgical System. Dr. Ramin performed the innovative surgery in July in Los Angeles using Robotics to remove a patient's pelvic cyst.

27 Aug 2009

Movember to present at the LIVESTRONG Global Cancer Summit

Staggering statistic: cancer kills more people every year than AIDS, tuberculosis and malaria combined. Joining more than 250 advocates from around the world, Adam Garone, co-founder and CEO of Movember, the world's largest charity for men's health, will present at the LIVESTRONG Global Cancer Summit in Dublin, Ireland, August 24 - 26.

27 Aug 2009

New website launched for comparing mortality risks by gender, age, cause of death and geographic region

A new Web site, www.DeathRiskRankings.com, developed by researchers and students at Carnegie Mellon University, allows users to query publicly available data from the United States and Europe, and compare mortality risks by gender, age, cause of death and geographic region. The Web site not only gives the risk of dying within the next year, but it also ranks the probable causes and allows for quick side-by-side comparison between groups.

26 Aug 2009

Cannabis chemicals halt prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer.

26 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

New drug delivery system for delivering nanoparticles into the tissue

Scientists at UC Santa Barbara have discovered a potential new drug delivery system. The finding is a biological mechanism for delivery of nanoparticles into tissue. The results are published in this week's Proceedings of the National Academy of Sciences.

26 Aug 2009

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to a study in the August 26 issue of JAMA.

26 Aug 2009

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine.

25 Aug 2009

Capital Earnings & Research to launch prostate cancer awareness campaign

What did all the following businessmen have in common?

24 Aug 2009

High serum insulin levels linked with increased risk of prostate cancer

Demetrius Albanes, M.D., of the Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Bethesda, Md., and colleagues investigated the relationship of the level of serum insulin and glucose, as well as surrogate indices of insulin resistance, to the development of prostate cancer.

24 Aug 2009

Cannabis chemicals stop prostate cancer growth

Active chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer today.

21 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

Researchers at Wake Forest University School of Medicine have destroyed prostate cancer tumors in mice by injecting them with specially-coated, miniscule carbon tubes and then superheating the tubes with a brief zap of a laser.

20 Aug 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Urodynamix Technologies announces fiscal 2009 second-quarter financials

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

Fatostatin lowers the activity of genes associated with cholesterol synthesis

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

oBand uses the da Vinci Surgical System to perform the world's first robotic surgery in an outpatient surgical center

Movember to present at the LIVESTRONG Global Cancer Summit

New website launched for comparing mortality risks by gender, age, cause of death and geographic region

Cannabis chemicals halt prostate cancer growth

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

New drug delivery system for delivering nanoparticles into the tissue

Increased risk of death for men with heart conditions undergoing RT with hormone therapy for prostate cancer

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Capital Earnings & Research to launch prostate cancer awareness campaign

High serum insulin levels linked with increased risk of prostate cancer

Cannabis chemicals stop prostate cancer growth

Results of PCF funded study could impact the standard of care for prostate cancer patients

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

DNA-encased carbon nanotubes used for treating human prostate cancer tumors in mice

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in